G. Mason Morfit is President of ValueAct Capital, a governance-oriented investment fund with approximately $17 billion in assets under management. ValueAct Capital invests in a concentrated portfolio of public companies and works actively with their executives and boards of directors on issues of strategy, capital structure, M&A and talent management. The partners at ValueAct Capital have served on the Boards of Directors of 38 public companies. The firm also has the flexibility to execute going-private transactions for 100% control in select circumstances.
Mr. Morfit joined the board of directors of Microsoft Corporation (NASDQ: MSFT) in March 2014. He is a former director of Valeant Pharmaceuticals International (NYSE: VRX, TSX: VRX), CR Bard, Inc. (NYSE: BCR), Immucor, Inc. (NASDQ: BLUD), Advanced Medical Optics (NYSE: EYE), Solexa, Inc. (NASDQ: SLXA) and MSD Performance, Inc.
Prior to ValueAct Capital, Mr. Morfit worked in equity research for Credit Suisse First Boston’s health care group covering the managed care industry. He has an AB from Princeton University. He has spoken on issues of corporate governance and executive compensation at Stanford Law School’s Director’s College, the Graduate School of Business at Stanford University, and the Haas School of Business at the University of California, Berkeley.